AS1604498
AS1604498 is a highly specific competitive inhibitor of human NAMPT, with an IC50 of 44.4 nM. AS1604498 functionally inhibits NAMPT enzymatic activity, reduces nicotinamide mononucleotide production, decreases intracellular NAD levels, activates caspase 3/7 and induces cancer cell apoptosis. AS1604498 is applicable to research related to chronic myeloid leukemia.
For research use only. We do not sell to patients.
- CAS No.: 361465-74-9
- Formula: C19H17N3O2
- Molecular Weight:319.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
In Vitro
AS1604498 (0.032-10 μM; 48 h) inhibits THP-1 human leukemia cell growth with an IC50 of 198 nM, and this effect is reversed by 10 mM Nicotinamide (HY-B0150)[1].
AS1604498 (0.032-10 μM; 48 h) inhibits K562 human chronic myelogenous leukemia cell growth with an IC50 of 673 nM, and this effect is reversed by 10 mM Nicotinamide[1].
AS1604498 (10 μM; 48 h) induces delayed caspase 3/7 activation in THP-1 cells, and this activation is reversed by 10 mM Nicotinamide[1].
AS1604498 (0.001-10 μM; 5 h) reduces intracellular NAD levels in K562 cells in a dose-dependent manner, and this effect is reversed by 10 mM Nicotinamide[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:THP-1 human leukemia cell
-
Concentration:0.032, 0.1, 0.32, 1, 3.2, 10 μM
-
Incubation Time:48 h
-
Result:Dose-dependently inhibited THP-1 cell proliferation, with an IC50 of 198 nM (equivalent to 198 nM).
Was completely reversed in growth inhibitory effect by the addition of 10 mM nicotinamide.
-
Cell Line:K562 human chronic myelogenous leukemia cell
-
Concentration:0.032, 0.1, 0.32, 1, 3.2, 10 μM
-
Incubation Time:48 h
-
Result:Dose-dependently inhibited K562 cell proliferation, with an IC50 of 673 nM (equivalent to 673 nM).
Was completely reversed in growth inhibitory effect by the addition of 10 mM nicotinamide.
Chemical Information
-
CAS No. 361465-74-9
-
Molecular Weight 319.36
-
Formula C19H17N3O2
-
SMILES
O=C(NCCCN1C=NC=C1)C=2OC(C#CC=3C=CC=CC3)=CC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- AS1604498
- 361465-74-9
- AS 1604498
- AS-1604498
- NAMPT
- Caspase
- Apoptosis
- NAMPT dimer interface pocket
- cancer cells
- K562 human chronic myelogenous leukemia cell
- NAMPT enzyme activity
- caspase 3/7
- human NAMPT
- chronic myelogenous leukemia
- THP-1 human leukemia cell
- intracellular NAD levels
- nicotinamide mononucleotide
- Inhibitor
- inhibitor
- inhibit